Octavian

Octavian Therapeutics, formerly known as Oxford Cannabinoid Technologies, is a clinical-stage biopharmaceutical company focused on developing non-addictive treatments for chronic and neuropathic pain. The company's primary research centers on the endocannabinoid system, specifically targeting the cannabinoid receptor type 2 (CB2) with small-molecule agonists. Its lead clinical candidate, OCT461201, has completed Phase 1 trials for indications including diabetic peripheral neuropathy, chemotherapy-induced peripheral neuropathy, and irritable bowel syndrome. Octavian utilizes an AI-driven drug discovery platform and a library of over 2,000 new chemical entities to identify and optimize novel therapeutic candidates. Despite a strategic rebranding and fundraising efforts in early 2025, the company entered administration in May 2025 and has ceased all trading operations.